KalVista Pharmaceuticals (NASDAQ:KALV) Sets New 12-Month High Following Analyst Upgrade

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)’s stock price reached a new 52-week high during mid-day trading on Friday after Stifel Nicolaus raised their price target on the stock from $39.00 to $42.00. Stifel Nicolaus currently has a buy rating on the stock. KalVista Pharmaceuticals traded as high as $19.27 and last traded at $18.95, with a volume of 2400756 shares. The stock had previously closed at $17.14.

Several other research analysts have also recently weighed in on the company. Needham & Company LLC upped their price objective on KalVista Pharmaceuticals from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday. TD Cowen restated a “buy” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, December 3rd. HC Wainwright raised their target price on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research report on Friday, January 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Thursday, January 22nd. Finally, Wall Street Zen raised KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, December 6th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.60.

Insiders Place Their Bets

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 10,034 shares of KalVista Pharmaceuticals stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $15.57, for a total transaction of $156,229.38. Following the completion of the transaction, the chief executive officer directly owned 442,883 shares of the company’s stock, valued at $6,895,688.31. The trade was a 2.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Paul K. Audhya sold 5,354 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $15.57, for a total transaction of $83,361.78. Following the sale, the insider directly owned 138,983 shares of the company’s stock, valued at $2,163,965.31. The trade was a 3.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 33,378 shares of company stock valued at $522,290. 4.30% of the stock is owned by insiders.

KalVista Pharmaceuticals News Summary

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Company reported $49.1M in EKTERLY revenue during an eight‑month transition period and highlighted a strong launch that supports topline growth expectations. KalVista posts $49.1 million in EKTERLY revenue
• Positive Sentiment: Corporate update and eight‑month FY2025 results emphasized commercial progress and operational updates that underpin near‑term revenue visibility. KalVista Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update
• Positive Sentiment: Stifel Nicolaus raised its price target to $42 and kept a “buy” rating — implying ~122% upside from the current price — reflecting bullish analyst views on commercial execution and upside potential. Stifel raises KALV price target
• Positive Sentiment: Needham & Company increased its target from $35 to $36 and maintained a “buy” rating, signaling continued analyst confidence in EKTERLY’s market opportunity. Needham raises KALV price target
• Neutral Sentiment: Q1/8‑month earnings call transcripts (and related highlights) are available; these provide detail on revenue cadence, channel dynamics, and management commentary that investors should review for execution risk and guidance clarity. Q1 2025 earnings call transcript 8 Months 2025 earnings call transcript
• Negative Sentiment: Citizens Jmp trimmed its price target from $29 to $28 and moved to “market outperform” — a mild downgrade in target that could temper enthusiasm despite still-significant upside (~48%). Citizens Jmp lowers KALV price target

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets boosted its position in shares of KalVista Pharmaceuticals by 47.0% in the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after acquiring an additional 1,292 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of KalVista Pharmaceuticals in the third quarter valued at approximately $55,000. Wolverine Asset Management LLC acquired a new stake in KalVista Pharmaceuticals during the third quarter worth approximately $57,000. Truvestments Capital LLC grew its holdings in shares of KalVista Pharmaceuticals by 253.8% during the 4th quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock worth $76,000 after purchasing an additional 3,360 shares in the last quarter. Finally, KLP Kapitalforvaltning AS bought a new stake in KalVista Pharmaceuticals during the third quarter worth about $63,000.

KalVista Pharmaceuticals Price Performance

The firm has a market cap of $957.92 million, a P/E ratio of -4.80 and a beta of -0.35. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. The company’s 50-day moving average is $15.95 and its two-hundred day moving average is $14.44.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.